南新制药：2025年度业绩快报公告

Group 1 - The core point of the article is that Nanjing New Pharmaceutical reported a significant decline in revenue for the year 2025, with total operating income reaching 1,419.276 million yuan, a year-on-year decrease of 46.09% [2] Group 2 - The company’s performance indicates a substantial drop in revenue, which may raise concerns about its market position and operational efficiency moving forward [2] - The announcement was made on February 27, highlighting the urgency of the financial situation [2] - The reported figures suggest potential challenges in the pharmaceutical industry, particularly for companies experiencing such drastic revenue declines [2]